Tenofovir-induced Fanconi syndrome and osteomalacia in two HIV-infected patients: Role of intracellular tenofovir diphosphate levels and review of the literature

Scandinavian Journal of Infectious Diseases

Volumn 43, Issue 10, 2011, Pages 821-826

  Haverkort, Milly E ^a   Van Der Spek, Bas W ^b   Lips, Paul ^b   Slieker, Walentina A ^c   Ter Heine, Rob ^d   Huitema, Alwin D ^e   Bronsveld, Willem ^c  

^a Sionsberg Hospital   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Location Alkmaar   (Netherlands)

^d MEANDER MEDICAL CENTER   (Netherlands)

^e SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

Fanconi syndrome; FGF23; HIV; Osteomalacia; Renal insufficiency; Tenofovir

Indexed keywords

BICARBONATE; CALCITRIOL; CALCIUM; CREATININE; DELAVIRDINE; DIDANOSINE; ETRAVIRINE; FIBROBLAST GROWTH FACTOR 23; FOSAMPRENAVIR PLUS RITONAVIR; LACTIC ACID; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; PHOSPHATE; RALTEGRAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; VITAMIN D; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AIDS PATIENT; AMINOACIDURIA; ANTIVIRAL THERAPY; ARTICLE; BICARBONATE BLOOD LEVEL; BONE BIOPSY; BONE MARROW EDEMA; BONE SCINTISCANNING; CASE REPORT; CREATININE CLEARANCE; DELAYED DIAGNOSIS; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; FANCONI RENOTUBULAR SYNDROME; FEMUR PERTROCHANTERIC FRACTURE; FIBULA FRACTURE; GLUCOSURIA; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; HYPOKALEMIA; HYPOPHOSPHATEMIA; HYPOURICEMIA; LABORATORY TEST; LACTATE BLOOD LEVEL; MALE; MITOCHONDRIAL TOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOMALACIA; OSTEOPENIA; PATHOGENESIS; PHOSPHATE BLOOD LEVEL; STRESS FRACTURE; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

ADENINE; ADULT; ANTI-HIV AGENTS; DIPHOSPHATES; FANCONI SYNDROME; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; OSTEOMALACIA; WHOLE BODY IMAGING;

EID: 80052507396     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365548.2011.577805     Document Type: Article

References (20)

1. Labarga P, Barreiro P, Martin-Carbonero L, Rodriguez-Nóvoa S, Solera C, Medrano J, et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS 2009;23:689-96.
2. Kinai E, Hanabusa H. Progressive renal tubular dysfunction associated with long-term use of tenofovir DF. AIDS Res Hum Retroviruses 2009;25:387-94.
3. Pruvost A, Negredo E, Benech H, Theodoro F, Puig J, Grau E, et al. Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2005;49:1907-14. (Pubitemid 40631606)
4. Pruvost A, Negredo E, Théodoro F, Puig J, Levi M, Ayen R, et al. Pilot pharmacokinetic study of human immunodefi-ciency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracel-lular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir. Antimicrob Agents Chemother 2009;53: 1937-43.
5. Jansen RS, Rosing H, de Wolf CJ, Beijnen JH. Development and validation of an assay for the quantitative determination of cladribine nucleotides in MDCKII cells and culture medium using weak anion-exchange liquid chromatography coupled with tandem mass spectrometry. Rapid Commun Mass Spectrom 2007;21:4049-59.
6. Durand-Gasselin L, Da Silva D, Benech H, Pruvost A, Grassi J. Evidence and possible consequences of the phos-phorylation of nucleoside reverse transcriptase inhibitors in human red blood cells. Antimicrob Agents Chemother 2007;51:2105-11. (Pubitemid 46903101)
7. Ray AS, Cihlar T, Robinson KL, Tong L, Vela JE, Fuller MD, et al. Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother 2006;50:3297-304. (Pubitemid 44527501)
8. Van Rompay KK, Durand-Gasselin L, Brignolo LL, Ray AS, Abel K, Cihlar T, et al. Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects. Antimicrob Agents Chemother 2008;52: 3144-60.
9. Kiser JJ, Aquilante CL, Anderson PL, King TM, Carten ML, Fletcher CV. Clinical and genetic determinants of intracel-lular tenofovir diphosphate concentrations in HIV-infected patients. J Acquir Immune Defic Syndr 2008;47:298-303. (Pubitemid 351619414)
10. Rodríguez-Nóvoa S, Labarga P, D'Avolio A, Barreiro P, Albalate M, Vispo E, et al. Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. AIDS 2010;24:1064-6.
11. Kearney BP, Yale K, Shah J, Zhong X, Flaherty JF. Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment. Clin Pharmacokinet 2006;45:1115-24. (Pubitemid 44631390)
12. Herlitz LC, Mohan S, Stokes MB, Radhakrishnan J, D'Agati VD, Markowitz GS, et al. Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities. Kidney Int 2010;78:1171-7.
13. Barreiro P, Soriano V. Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir. J Antimicrob Chemother 2006;57:806-9.
14. Negredo E, Garrabou G, Puig J, Lòpez S, Morén C, Bellido R, et al. Partial immunological and mitochondrial recovery after reducing didanosine doses in patients on didanosine and tenofovir-based regimens. Antivir Ther 2008;13:231-40. (Pubitemid 351535374)
15. Kiser JJ, Carten ML, Aquilante CL, Anderson PL, Wolfe P, King TM, et al. The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clin Pharmacol Ther 2008;83:265-72.
16. Goicoechea M, Liu S, Best B, Sun S, Jain S, Kemper C, et al. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis 2008;197:102-8. (Pubitemid 351263473)
17. Rodríguez-Nóvoa S, Labarga P, Soriano V, Egan D, Albalater M, Morello J, et al. Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmaco-genetic study. Clin Infect Dis 2009;48:108-16.
18. Izzedine H, Hulot JS, Villard E, Goyenvalle C, Dominguez S, Ghosn J, et al. Association between ABCC2 gene haplo-types and tenofovir-induced proximal tubulopathy. J Infect Dis 2006;194:1481-91. (Pubitemid 44851889)
19. Durand-Gasselin L, Van Rompay KK, Vela JE, Henne IN, Lee WA, Rhodes GR, et al. Nucleotide analogue prodrug tenofovir disoproxil enhances lymphoid cell loading following oral administration in monkeys. Mol Pharm 2009;6: 1145-51.
20. Saidenberg-Kermanac'h N, Souabni L, Prendki V, Prie D, Boissier M-C, et al. Normal plasma FGF23 levels kinetic in tenofovir-related hypophosphatemic osteomalacia in an HIV-infected patient with von Recklinghausen disease. Joint Bone Spine 2010; [Epub ahead of print].